Back

Allogenetics raises €3.8 million for lung-transplant gene therapy

Verifying
  • Allogenetics completed a €3.8 million Pre-Series A financing round led by NBank Capital.
  • The proceeds will fund ALG-115 IND-enabling studies for lung transplantation.
  • First-in-human trials are planned between the end of 2027 and early 2028.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.